Maureen A Mealy
8PUBLICATIONS
16CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (8)
Sort by Publication Date:
|Oct 01, 2021
Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: Analysis of aquaporin-4-immunoglobulin G-seropositive participants taking inebilizumab for ⩾4 years in the N-MOmentum trial.Mary Rensel, Aram Zabeti, Maureen A Mealy
|Aug 27, 2021
B-Cell Targeted Treatments for Neuromyelitis Optica Spectrum Disorder: A Focus on CD19 and CD20.Michael Levy, Maureen A Mealy
|Apr 10, 2020
Scrambler therapy improves pain in neuromyelitis optica: A randomized controlled trial.Maureen A Mealy, Sharon L Kozachik, Lawrence J Cook
|Aug 01, 2019
Aquaporin-4 IgG seropositivity is associated with worse visual outcomes after optic neuritis than MOG-IgG seropositivity and multiple sclerosis, independent of macular ganglion cell layer thinning.Elias S Sotirchos, Angeliki Filippatou, Kathryn C Fitzgerald
|Jul 13, 2019
MRI Predictors of Recurrence and Outcome after Acute Transverse Myelitis of Unidentified Etiology.E Bulut, T Shoemaker, J Karakaya
|Dec 19, 2018
Updated diagnostic criteria for neuromyelitis optica spectrum disorder: Similar outcomes of previously separate cohorts.M McCreary, M A Mealy, D M Wingerchuk
Pageof 2
